Guardant Health, a three-year-old, Redwood Shores, Ca.-based company whose non-invasive genomic sequencing test for cancer requires just two vials of blood, has raised nearly $100 million in Series D funding roughly one year after closing on $90 million for its Series C round.
The financing was led by OrbiMed Advisors, with earlier backers participating, including Khosla Ventures, Sequoia… Read More...